

FOI 3212

31<sup>st</sup> July 2025

**FREEDOM OF INFORMATION ACT 2000 – INFORMATION REQUEST**

**ENC FOI 3212**

**Question 1. Does your trust provide SACT (systemic anti-cancer therapy) treatments for endometrial cancer? If not, which other trust do you refer endometrial cancer patients to for SACT treatments?**

**Question 2. How many patients were treated for endometrial cancer (any stage) in the past three months with the following treatments:**

- Dostarlimab (Jemperli)
- Dostarlimab (Jemperli) AND Chemotherapy
- Hormone therapy (Progesterone or Letrozole)
- Pembrolizumab (Keytruda) monotherapy
- Lenvatinib + Pembrolizumab (Lenvima +Keytruda)
- Platinum-based chemotherapy (monotherapy or combination with taxanes, anthracyclines, cyclophosphamide)
- Any other SACT
- Any other Chemotherapy
- Durvalumab with platinum-based chemotherapy
- Pembrolizumab with platinum-based chemotherapy

**Question 3. Does your trust participate in any clinical trials for the treatment of endometrial cancer? If so, can you please provide the name of each trial and the number of patients taking part?**

**Response:**

We do not treat endometrial cancer in the Southern Trust. The patients attend Belfast Health & Social Care Trust for treatment; you can make contact with the Public Liaison team who are responsible for dealing with FOI requests within the Belfast Trust via e-mail at: [publicliaison@belfasttrust.hscni.net](mailto:publicliaison@belfasttrust.hscni.net).

Email: [Foi.Team@Southerntrust.hscni.net](mailto:Foi.Team@Southerntrust.hscni.net)